Background: Identification of the antitumor role of tyrosine kinase inhibitors, such as TKI-258, may lead to novel therapeutics for Oral Squamous Cell Carcinoma (OSCC), which has high mortality rates. TKI-258 blocks Fibroblast Growth Factor Receptors (FGFRs), Platelet-Derived Growth Factor Receptors (PDGFRs), and Endothelial Growth Factor Receptor (VEGFRs).
Objective: This study aimed to evaluate the effect of TKI-258 treatment on cell proliferation in SCC-4 cells of OSCC.
Methods: BrdU and KI-67 assays were performed by using SCC-4 cells. Control was compared to 1, 5 and 10μM TKI-258 treatment. Control vehicle was compared to: 60μM LY294002 (LY), 2μM Wortmannin (WTN) and LY+WNT. Moreover, TKI 5μM treatment was compared to: TKI 5μM+LY; TKI 5 μM+WTN; TKI 5μM+LY+WTN. After 6h of treatments, immunofluorescence stained BrdU and KI-67 positive cells. Morphometry of proliferative cells was analyzed considering significance of p<0.05.
Results: BrdU and KI-67 assays results were similar for all experiments. TKI-258 treatment leads to an important reduction in proliferation rate in SCC-4 cells in a concentration dependent manner. As expected, there was a significant reduction in the percentage of proliferative cells that had PI3K inhibited. When compared with TKI 5 treatment, proliferating cells were significantly lower with simultaneous PI3K inhibition.
Conclusion: This study demonstrated that TKI-258 plays an anti-proliferative role on SCC-4 cells of OSCC. It could be interesting to block multiples pathways such as FGFRs, PDGFRs and VEGFRs. Therefore, TKI-258 is a promising option for novel therapeutics for OSCC, especially if associated with PI3K inhibition.
[http://dx.doi.org/10.2174/18715206113139990110] [PMID: 23194421]
[http://dx.doi.org/10.1016/j.joms.2014.12.030] [PMID: 25883000]
[http://dx.doi.org/10.1021/jm800790t] [PMID: 19113866]
[http://dx.doi.org/10.1097/CAD.0000000000000405] [PMID: 27400375]
[http://dx.doi.org/10.1016/j.oraloncology.2012.06.011] [PMID: 22795534]
[http://dx.doi.org/10.1016/j.oraloncology.2014.11.012] [PMID: 25532816]
[http://dx.doi.org/10.1007/s00432-016-2161-0] [PMID: 27100354]
[http://dx.doi.org/10.1016/S1470-2045(14)70030-0] [PMID: 24556040]
[http://dx.doi.org/10.4161/15384101.2014.995050] [PMID: 25714853]